Find A Multiple Myeloma Trial
Search for a multiple myeloma clinical trial. You may need to satisfy additional criteria in order to be eligible for a study.

Talk With a Patient Navigator
For additional support click here to get connected with a patient navigator. Learn More About Clinical Trials


Keyword Search
Zip Code
Condition Status
For assistance with trials outside the United States, please contact patientnavigator@themmrf.org
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Horizon is a Phase 3 trial for patients with relapsed or refractory multiple myeloma who have received 2 or more prior therapies and have not received a treatment that targets BCMA. The goal of the study is to compare the effectiveness and safety of the investigational BCMA-targeting bispecific antibody, elranatamab, to standard treatment options.

Sponsored By Multiple Myeloma Research Foundation
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
In this clinical study, researchers are exploring a unique approach to treating Multiple Myeloma by combining different therapies, including a specific type of antibody treatment. This study stands out because it focuses on the effectiveness of these combinations in patients who have already undergone other treatments. The goal is to improve patient outcomes and provide new options for those with this condition.

Featured Trial
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
iMMagine-3 is a phase 3, randomized clinical trial for people with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and immunomodulatory drug. The goal of the study is to evaluate if anitocabtagene autoleucel (anito-cel) is more effective than standard of care treatment (PVd, DPd, KDd, or Kd), as measured by progression free survival (the amount of time before the disease worsens).

Featured Trial
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02199665
Age 18 +
Sex Both
Phase Phase 1
This study is testing the safety and effectiveness of combining selinexor, carfilzomib, and dexamethasone to treat multiple myeloma that has returned or is not responsive to other treatments. These drugs work in different ways to stop cancer cells from growing, dividing, or spreading.
Third Opinion AI Generated Synopsis

Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02343042
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining multiple therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well these combined treatments work compared to standard options, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
NCT03275103
Age 18 +
Sex Both
Phase Phase 1
This is a study where the drug cevostamab is given to patients with relapsed or refractory multiple myeloma through an IV infusion. The study aims to test the safety and effectiveness of different doses of cevostamab.
Third Opinion AI Generated Synopsis

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078
Age 18 +
Sex Both
Phase Phase 2
A study will be conducted to evaluate the efficacy and safety of bb2121 in subjects with multiple myeloma who have relapsed, progressed within a certain time frame, or have had an inadequate response to prior treatments. The study will enroll approximately 235 subjects across three cohorts, and will also include newly diagnosed multiple myeloma participants with suboptimal response to autologous stem cell transplantation.
Third Opinion AI Generated Synopsis

High Dose Ascorbic Acid for Plasma Cell Disorders
NCT03602235
Age 18 +
Sex Both
Phase Phase 1
The study is testing the safety and effectiveness of a combination of low dose melphalan and high dose ascorbate acid in patients with multiple myeloma who have already relapsed or become resistant to previous treatments. It is a Phase I clinical trial.
Third Opinion AI Generated Synopsis

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
NCT03710421
Age 18 +
Sex Both
Phase Phase 1
The study is testing the side effects and appropriate dosage of a therapy called CS1-CAR T, which modifies immune cells to kill cancer cells in patients with CS1-positive multiple myeloma that has relapsed or not responded well to previous treatments. CS1-CAR T cells are engineered immune cells that recognize and eliminate cancer cells.
Third Opinion AI Generated Synopsis

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718
Age 18 - 80
Sex Both
Phase Phase 2
The study aims to evaluate the effectiveness of combining daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in treating people with relapsed and refractory Multiple Myeloma, a condition in which previously treated Multiple Myeloma returns or becomes resistant to treatment.
Third Opinion AI Generated Synopsis

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
NCT04302324
Age 18 - 75
Sex Both
Phase Phase 2
This study will test a new treatment for relapsed/refractory multiple myeloma using daratumumab in combination with clarithromycin/pomalidomide/dexamethasone until progressive disease or unacceptable toxicity occurs, with the hypothesis that this combination will yield higher Very Good Partial Response rates than the historical pomalidomide/dexamethasone treatment.
Third Opinion AI Generated Synopsis

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04405167
Age 18 +
Sex Both
Phase Phase 1
The study is the first to examine the effects of tasquinimod, an inhibitor of S100A9, in people with multiple myeloma.
Third Opinion AI Generated Synopsis

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623
Age 18 +
Sex Both
Phase Phase 3
The study will compare the effectiveness and safety of belantamab mafodotin combined with pomalidomide and dexamethasone to a combination of pomalidomide, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
Third Opinion AI Generated Synopsis

Selinexor, Pomalidomide, and Dexamethasone with or Without Carfilzomib for the Treatment of Patients with Relapsed Refractory Multiple Myeloma, the SCOPE Trial
NCT04764942
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works compared to standard treatments, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on using a combination of therapies that target the disease in different ways, potentially improving patient outcomes. The study aims to assess how well this innovative treatment works compared to standard options.
Third Opinion AI Generated Synopsis

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04883242
Age 18 +
Sex Both
Phase Phase 2
This trial tests the effectiveness of a treatment consisting of a monoclonal antibody, a protein blocker, a tumor cell growth inhibitor, and an anti-inflammatory drug in patients with multiple myeloma that has relapsed or is unresponsive to treatment. The treatment aims to kill more cancer cells by interfering with their growth and spread.
Third Opinion AI Generated Synopsis

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
NCT04960579
Age 18 +
Sex Both
Phase Phase 1
The study involved testing of P-BCMA-ALLO1 allogeneic T stem cell memory CAR-T cells in several groups of individuals with relapsed or refractory Multiple Myeloma. The study is the first phase of a larger clinical trial involving the CAR-T cells.
Third Opinion AI Generated Synopsis

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997
Age 18 +
Sex Both
Phase Phase 3
This study aims to compare the effectiveness and safety of two different treatments for relapsed or refractory multiple myeloma. One treatment includes iberdomide, dexamethasone and daratumumab, while the other includes daratumumab, bortezomib, and dexamethasone.
Third Opinion AI Generated Synopsis

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
NCT05007418
Age 18 +
Sex Both
Phase Phase 1
This is a clinical trial where the drug STI-1492 is given to people with multiple myeloma who have not responded to previous treatments. The drug is administered intravenously in increasing amounts to determine the best dosage.
Third Opinion AI Generated Synopsis

TriPRIL CAR T Cells in Multiple Myeloma
NCT05020444
Age 18 +
Sex Both
Phase Phase 1
The study aims to test TriPRIL CAR T Cells for treating people with multiple myeloma and evaluate any side effects, along with standard chemotherapy drugs used in the treatment process.
Third Opinion AI Generated Synopsis

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566
Age 18 +
Sex Both
Phase Phase 2
The study aims to find the recommended dose and clinical impact of elranatamab when used in combination with other anti-cancer therapies for treating multiple myeloma patients.
Third Opinion AI Generated Synopsis

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Age 18 +
Sex Both
Phase Phase 1
The study will assess the safety and toxicity of investigational drug ABBV-383 when given with other medications to adult patients with relapsed/refractory multiple myeloma. The study will include a dose escalation and dose expansion phase, with approximately 270 participants at sites worldwide, and treatment burden may be higher than standard of care.
Third Opinion AI Generated Synopsis

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique approach to treatment by combining different therapies to enhance effectiveness against the disease. The trial focuses on using a specific combination of medications that have shown promise in previous studies, aiming to improve patient outcomes. This innovative strategy may offer new hope for individuals seeking effective treatment options.
Third Opinion AI Generated Synopsis

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
NCT05427812
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique approach to treating patients with Multiple Myeloma by using a combination of therapies that target specific pathways involved in the disease. This study stands out because it focuses on a personalized treatment plan that adapts to the individual needs of each patient, potentially leading to more effective outcomes. By integrating various treatment modalities, the study aims to improve the overall management of the condition and enhance patients' quality of life.
Third Opinion AI Generated Synopsis

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05431608
Age 18 +
Sex Both
Phase Phase 1
Participants' T cells will be turned into study therapies MCARH109 and MCARH125. Participants will get either MCARH125 by itself or MCARH125 combined with MCARH109.
Third Opinion AI Generated Synopsis

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
NCT05514990
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works compared to standard treatments, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

LMY-920 for Treatment of Relapsed or Refractory Myeloma
NCT05546723
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that involves a combination of therapies aimed at enhancing the immune response. What makes this trial unique is its focus on using a specific type of immune cell activation alongside traditional treatments, which may lead to improved outcomes. This innovative strategy could potentially offer a more effective way to manage the disease and improve patient quality of life.
Third Opinion AI Generated Synopsis

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515
Age 18 +
Sex Both
Phase Phase 3
This study aims to determine if teclistamab is as effective as PVd/Kd for a specific purpose.
Third Opinion AI Generated Synopsis

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05650632
Age 18 +
Sex Both
Phase Phase 1
This study is testing a new drug, ABBV-383, for the treatment of relapsed/refractory Multiple Myeloma. The study will enroll around 80 adult participants who will receive the drug through an infusion in 28 day cycles for approximately 3 years. Regular visits, medical assessments, blood tests, and questionnaires will be conducted to assess the treatment's effectiveness and any side effects.
Third Opinion AI Generated Synopsis

A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
NCT05651932
Age 18 +
Sex Both
Phase Phase 1
This study aims to test the safety of a new orally available drug that can inhibit an enzyme called MMSET in patients with relapsed or refractory multiple myeloma, a type of cancer, by preventing a specific chemical modification in cells.
Third Opinion AI Generated Synopsis

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036
Age 18 +
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a unique treatment approach that combines multiple therapies to target specific aspects of the disease. This study stands out because it focuses on a combination of existing treatments and new strategies to enhance patient outcomes. By investigating how these therapies work together, the study aims to improve the effectiveness of treatment for patients.
Third Opinion AI Generated Synopsis

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
NCT05789303
Age 18 +
Sex Both
Phase Phase 2
In this study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well these combined treatments work compared to standard options.
Third Opinion AI Generated Synopsis

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies that target the disease in innovative ways, potentially improving patient outcomes. This trial is distinctive because it involves a multi-faceted treatment strategy that aims to enhance the effectiveness of existing therapies.
Third Opinion AI Generated Synopsis

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
NCT05862012
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a new treatment approach that combines different therapies to target Multiple Myeloma more effectively. What makes this trial unique is its focus on using a specific combination of drugs that have shown promise in earlier studies, aiming to improve patient outcomes. Participants will receive personalized treatment plans based on their individual responses, which could lead to more tailored and effective care.
Third Opinion AI Generated Synopsis

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
NCT05896228
Age 18 - 75
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works compared to standard treatments, providing valuable insights into more effective care options.
Third Opinion AI Generated Synopsis

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
NCT05911321
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to improve outcomes for patients. What makes this trial unique is its focus on a specific combination of treatments that target the disease in innovative ways, potentially leading to better management of symptoms and improved quality of life. The study aims to gather valuable data on how these treatments work together, which could pave the way for more effective options in the future.
Third Opinion AI Generated Synopsis

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT05981209
Age 18 +
Sex Both
Phase Phase 1
This clinical study focuses on a unique treatment approach for patients with Multiple Myeloma by utilizing a combination of therapies that target specific pathways involved in the disease. It aims to improve patient outcomes by enhancing the effectiveness of existing treatments while minimizing side effects. The study also emphasizes the importance of personalized medicine, tailoring therapies to individual patient profiles for better results.
Third Opinion AI Generated Synopsis

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
NCT06048250
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining multiple therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to assess how well this combination works compared to standard treatments, providing valuable insights into more effective care options.
Third Opinion AI Generated Synopsis

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
NCT06050512
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to assess how well these combined treatments work in managing the disease and potentially offering better options for patients.
Third Opinion AI Generated Synopsis

18F-Fluciclovine PET/CT in Multiple Myeloma
NCT06103838
Age 18 - 120
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that involves using a combination of therapies to enhance effectiveness. What makes this trial unique is its focus on integrating various treatment methods to improve patient outcomes and potentially reduce side effects. Participants will be closely monitored to assess the impact of this innovative strategy on their health and recovery.
Third Opinion AI Generated Synopsis

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT06115135
Age Any Age.
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique combination of treatments for patients with a specific type of blood cancer. The study focuses on using a combination of therapies that have shown promise in previous trials, aiming to improve patient outcomes and potentially enhance the effectiveness of existing treatments. This innovative approach may offer new hope for patients by targeting the disease more effectively and reducing side effects.
Third Opinion AI Generated Synopsis

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685
Age 18 +
Sex Both
Phase Phase 1, Phase 2
This clinical study focuses on a unique combination of treatments for patients with Multiple Myeloma, utilizing a specific approach that integrates various therapies to enhance effectiveness. It aims to evaluate how well these combined treatments work in managing the condition and improving patient outcomes. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Age 18 +
Sex Both
Phase Phase 1
This study focuses on a unique approach to treating patients by evaluating a specific combination of therapies that target the disease more effectively. It aims to enhance patient outcomes by using a tailored treatment plan that considers individual responses. The study also emphasizes the importance of monitoring and adjusting therapies based on real-time data from participants.
Third Opinion AI Generated Synopsis

Elranatamab in R/R Multiple Myeloma
NCT06138275
Age 18 +
Sex Both
Phase Phase 2
This clinical study focuses on a unique approach to treating Multiple Myeloma by utilizing a combination of therapies that target specific pathways involved in the disease. It aims to evaluate the effectiveness of this combination in improving patient outcomes and reducing disease progression. The study also emphasizes the importance of personalized treatment plans based on individual patient characteristics.
Third Opinion AI Generated Synopsis

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251
Age 18 +
Sex Both
Phase Phase 1
This clinical study focuses on a unique approach to treating Multiple Myeloma by utilizing a combination of therapies that have shown promise in previous research. It aims to enhance patient outcomes by integrating innovative treatment strategies and monitoring their effectiveness closely. Participants will receive personalized care tailored to their specific needs, which may lead to improved management of their condition.
Third Opinion AI Generated Synopsis

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO)
NCT06158841
Age 18 +
Sex Both
Phase Phase 3
Cervino is a Phase 3 trial for patients with relapsed or refractory multiple myeloma who have received 2 or more prior therapies and have not received a treatment that targets BCMA. The goal of the study is to compare the effectiveness and safety of the investigational BCMA-targeting bispecific antibody, etentamig, to standard treatment options.

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
NCT06185751
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique approach to treating Multiple Myeloma by using a combination of therapies that target specific pathways involved in the disease. The study focuses on the use of a new treatment regimen that includes both established and innovative therapies, aiming to improve patient outcomes and reduce side effects. This trial is distinctive because it emphasizes personalized treatment plans based on individual patient characteristics and disease profiles.
Third Opinion AI Generated Synopsis

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT06203912
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to assess how well this combination works compared to standard treatments, providing valuable insights into more effective care options.
Third Opinion AI Generated Synopsis

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a unique combination treatment for patients, which includes a specific type of therapy that targets the cancer cells more effectively. The trial focuses on how this combination can improve patient outcomes and potentially lead to better management of the condition. By using a novel approach, the study aims to enhance the effectiveness of existing treatments and provide new options for patients.
Third Opinion AI Generated Synopsis

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a unique approach to treating patients by using a combination of therapies that target specific aspects of the disease. The trial focuses on the use of advanced techniques to enhance the effectiveness of treatment, potentially leading to better outcomes for patients. This innovative strategy aims to improve the overall management of the condition and may offer new hope for those affected.
Third Opinion AI Generated Synopsis

A Trial of Selinexor, Ruxolitinib and Methylprednisolone
NCT06225310
Age Any Age.
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique treatment approach that combines a specific drug with a targeted delivery method to enhance its effectiveness against Multiple Myeloma. This study stands out because it focuses on using advanced techniques to improve how the drug reaches the cancer cells, potentially leading to better outcomes for patients. By investigating this innovative strategy, the study aims to provide new options for managing the disease more effectively.
Third Opinion AI Generated Synopsis

Hypofractionation (Radiation) Trial for Multiple Myeloma
NCT06270888
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to enhance the effectiveness of existing treatments, potentially leading to better outcomes for patients. This innovative strategy may provide new options for those who have not responded well to standard therapies.
Third Opinion AI Generated Synopsis

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226
Age 18 +
Sex Both
Phase Phase 2
In this study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines different therapies to enhance effectiveness. What makes this trial unique is its focus on using a specific combination of drugs that have shown promise in previous studies, aiming to improve patient outcomes. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
NCT06304636
Age 18 +
Sex Both
Phase Phase 1
This study focuses on a unique approach to treating patients with Multiple Myeloma by evaluating the effectiveness of a specific combination therapy. It aims to enhance patient outcomes by targeting the disease more effectively and improving overall treatment responses. The trial also emphasizes the importance of patient participation and the potential for personalized treatment strategies.
Third Opinion AI Generated Synopsis

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT06351644
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on a combination of therapies that have not been widely tested together before, potentially offering a more effective treatment option. The study aims to evaluate how well this new combination works in improving patient outcomes compared to standard treatments.
Third Opinion AI Generated Synopsis

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
NCT06381141
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique treatment approach for patients with Multiple Myeloma by using a combination of therapies that target specific aspects of the disease. The study focuses on the effectiveness of this combination in improving patient outcomes and aims to provide insights into how these treatments can be tailored for better results. This innovative strategy may offer new hope for patients by enhancing the overall management of their condition.
Third Opinion AI Generated Synopsis

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT06433947
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a new treatment approach that combines different therapies to enhance effectiveness against the disease. What makes this trial unique is its focus on using a combination of agents that target multiple pathways, potentially leading to better outcomes for patients. This innovative strategy aims to improve the overall management of the condition and may offer new hope for those affected.
Third Opinion AI Generated Synopsis

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
NCT06465316
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to assess how well this combination works compared to standard treatments, potentially offering a more effective option for managing the disease.
Third Opinion AI Generated Synopsis

ATRA and Carfilzomib in Plasma Cell Myeloma Patients
NCT06536413
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach for patients with Multiple Myeloma by combining different therapies to enhance effectiveness. The study focuses on using a specific combination of medications that target the disease in innovative ways, potentially leading to improved outcomes for patients. This trial aims to provide insights into how these combined treatments can better manage the condition and improve patient quality of life.
Third Opinion AI Generated Synopsis

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT06588660
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique treatment approach for patients with Multiple Myeloma by combining different therapies to enhance effectiveness. The study focuses on a specific combination of medications that may improve patient outcomes and reduce side effects compared to traditional treatments. This innovative strategy aims to provide a more personalized treatment plan tailored to individual patient needs.
Third Opinion AI Generated Synopsis

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479
Age 18 +
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a unique approach to treating Multiple Myeloma by combining different therapies, including a specific type of antibody treatment. This study stands out because it focuses on the effectiveness of these combinations in patients who have already undergone other treatments. The goal is to improve patient outcomes and provide new options for those with this condition.
Third Opinion AI Generated Synopsis

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT06622005
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique combination treatment for patients with a specific type of blood cancer. The study focuses on using a combination of therapies that have not been previously tested together, aiming to improve patient outcomes. This innovative approach may provide new options for managing the disease and enhancing the quality of life for those affected.
Third Opinion AI Generated Synopsis

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
NCT06627751
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining multiple therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works compared to standard treatments, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
NCT06785415
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that may enhance the effectiveness of existing treatments, potentially leading to better outcomes for patients. This innovative strategy aims to improve patient responses and overall health by targeting the disease more effectively.
Third Opinion AI Generated Synopsis

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
NCT06876142
Age 18 - 120
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique combination therapy that targets specific pathways in the body to improve treatment outcomes. This approach aims to enhance the effectiveness of existing treatments by using a personalized strategy tailored to individual patient profiles. By focusing on the interaction between different treatment modalities, the study seeks to provide a more comprehensive and effective management plan for patients.
Third Opinion AI Generated Synopsis

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
NCT06940297
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well these combined treatments work compared to standard options, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
NCT06171685
Age 18 - 99
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to improve outcomes for patients. What makes this trial unique is its focus on using a combination of existing treatments in a novel way, which may enhance effectiveness and reduce side effects. This innovative strategy aims to provide better management options for patients facing challenges with their current treatment regimens.
Third Opinion AI Generated Synopsis

Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06711705
Age 18 +
Sex Both
Phase Phase 2
This clinical study focuses on a unique treatment approach for patients with Multiple Myeloma, utilizing a combination of therapies that have shown promise in previous research. It aims to evaluate the effectiveness of this combination in improving patient outcomes and reducing disease progression. The study also emphasizes the importance of patient participation and the potential for personalized treatment plans based on individual responses.
Third Opinion AI Generated Synopsis

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04508790
Age 18 +
Sex Both
Phase Phase 2
This phase II trial looks at how well leflunomide, pomalidomide, and dexamethasone work for treating multiple myeloma that has come back or does not respond to treatment. The combination of these drugs may work better than using pomalidomide and dexamethasone alone, by blocking cancer cell growth, inducing changes in the body's immune system, and stopping the growth and spread of tumor cells.
Third Opinion AI Generated Synopsis

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091257
Age 18 +
Sex Both
Phase Phase 1
The study aims to investigate whether Trametinib and Dabrafenib could be effective treatments for multiple myeloma.
Third Opinion AI Generated Synopsis

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
NCT05002816
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to evaluate how well these combined treatments work compared to standard options, potentially offering new hope for better management of the condition.
Third Opinion AI Generated Synopsis

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885
Age 18 +
Sex Both
Phase Phase 2
A Phase II study evaluated the effectiveness of CART-ddBCMA, a CAR-T cell therapy directed towards BCMA, in patients with relapsed or refractory multiple myeloma, a type of cancer. This study aimed to assess if CART-ddBCMA could be a potential treatment option for these patients.
Third Opinion AI Generated Synopsis

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
NCT04519476
Age 18 +
Sex Both
Phase Phase 1
This study aims to test whether selinexor is safe and effective in treating multiple myeloma patients who have not responded to a treatment involving lenalidomide, with or without steroids.
Third Opinion AI Generated Synopsis

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT04835129
Age 18 +
Sex Both
Phase Phase 2
The study aims to test the effectiveness of a combination of isatuximab, elotuzumab, pomalidomide, and dexamethasone in treating multiple myeloma. The trial includes patients who have relapsed and received at least two prior treatments.
Third Opinion AI Generated Synopsis

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Age 18 +
Sex Both
Phase Phase 1
In this clinical trial, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this study unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. Participants will receive a tailored treatment plan that may offer new hope for managing their condition.
Third Opinion AI Generated Synopsis

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418
Age 18 +
Sex Both
Phase Phase 1
This study aims to test a new treatment called CB-011, which uses CAR-T cell therapy to target a specific protein in multiple myeloma. The study will evaluate the safety, dosage, and effectiveness of CB-011 in patients with relapsed or refractory multiple myeloma.
Third Opinion AI Generated Synopsis

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT03761108
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on a combination of therapies that aim to enhance the effectiveness of existing treatments while minimizing side effects. This innovative strategy could potentially lead to improved outcomes for patients by targeting the disease more effectively.
Third Opinion AI Generated Synopsis

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
NCT04398745
Age 18 +
Sex Both
Phase Phase 1
This study aims to evaluate the safety and effectiveness of belantamab mafodotin, an anti-cancer drug, in patients with multiple myeloma who have renal impairment. The study will be conducted in two parts, with participants receiving the drug at a dose of either 2.5mg/kg or 1.9mg/kg every three weeks until disease progression or other endpoints occur.
Third Opinion AI Generated Synopsis

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
NCT04640779
Age 18 +
Sex Both
Phase Phase 1
This trial is testing the safety and optimal dosage of combining choline salicylate and selinexor in patients with non-Hodgkin or Hodgkin lymphoma, multiple myeloma, or histiocytic/dendritic cell neoplasm. Choline salicylate is an anti-inflammatory drug that reduces immune response, while selinexor works by blocking a protein necessary for cancer cell growth. The study aims to provide more information about the effectiveness of this drug combination in treating these types of cancer.
Third Opinion AI Generated Synopsis

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
NCT04661137
Age 18 +
Sex Both
Phase Phase 2
This study will examine the response rate of patients with multiple myeloma receiving selinexor in combination with carfilzomib, daratumumab, or pomalidomide. Patients will be assigned to the groups based on their current treatment and will continue treatment until disease progression, death, toxicity, or withdrawal.
Third Opinion AI Generated Synopsis

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique approach to treatment by combining different therapies to enhance effectiveness against the disease. The study focuses on using a specific combination of medications that target various aspects of the condition, potentially leading to improved patient outcomes. This innovative strategy aims to provide a more comprehensive treatment option for individuals facing this health challenge.
Third Opinion AI Generated Synopsis

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
NCT04822337
Age 18 +
Sex Both
Phase Phase 1, Phase 2
This clinical study focuses on a unique combination of treatments for patients, aiming to enhance the effectiveness of existing therapies. It explores the use of a specific drug regimen that targets multiple pathways involved in the disease, potentially leading to improved outcomes. By investigating this innovative approach, the study seeks to provide new options for managing the condition more effectively.
Third Opinion AI Generated Synopsis

Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
NCT04892446
Age 18 +
Sex Both
Phase Phase 2
This study aims to evaluate the safety and efficacy of magrolimab in combination with other anticancer therapies for participants with relapsed/refractory multiple myeloma, with a focus on determining the recommended phase 2 dose and measuring the objective response rate.
Third Opinion AI Generated Synopsis

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04942067
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works compared to standard treatments.
Third Opinion AI Generated Synopsis

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique combination of treatments for patients with a specific type of blood cancer. The study focuses on using a new approach that combines different therapies to enhance effectiveness and improve patient outcomes. This innovative strategy aims to target the disease more effectively, potentially leading to better management and quality of life for participants.
Third Opinion AI Generated Synopsis

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
NCT05065047
Age 18 +
Sex Both
Phase Phase 1
This clinical research aims to determine if the use of belantamab mafodotin (Blenrep) can prevent the recurrence of multiple myeloma in patients who have undergone an autologous stem cell transplant. The study will also analyze the safety of the drug in the post-transplant period.
Third Opinion AI Generated Synopsis

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
NCT05346809
Age 18 +
Sex Both
Phase Phase 2
This study will test whether Isatuximab can improve the immune system of patients with multiple myeloma or lymphoma after autologous stem cell transplantation, to better fight their cancer. Participants will be randomly assigned to two groups, with around two-thirds receiving Isatuximab in addition to the standard transplant procedure.
Third Opinion AI Generated Synopsis

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085
Age 18 +
Sex Both
Phase Phase 3
This study aims to compare the effectiveness and safety of CC-92480, bortezomib, and dexamethasone with pomalidomide, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma who have undergone 1 to 3 prior treatment lines and experienced lenalidomide exposure.
Third Opinion AI Generated Synopsis

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
NCT06055075
Age 18 +
Sex Both
Phase Phase 1, Phase 2
The study focuses on a unique approach to treating patients by combining various therapies to enhance effectiveness. It aims to evaluate the safety and effectiveness of these combinations, which may lead to improved outcomes for individuals. This innovative strategy could provide new options for managing the condition more effectively.
Third Opinion AI Generated Synopsis

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044
Age 18 +
Sex Both
Phase Phase 1
This study focuses on a unique approach to treating patients by evaluating the effectiveness of a specific treatment regimen that combines multiple therapies. It aims to assess how well this combination can improve patient outcomes and manage symptoms. The study is notable for its comprehensive design, which includes various patient demographics and treatment responses, providing valuable insights into personalized care.
Third Opinion AI Generated Synopsis

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498
Age 18 +
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a unique approach to treating patients by combining a specific therapy with standard care to enhance effectiveness. The study focuses on how this combination can improve outcomes for individuals, particularly those who have not responded well to previous treatments. By investigating this new method, the trial aims to provide insights that could lead to better management strategies for patients.
Third Opinion AI Generated Synopsis

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
NCT06827860
Age 70 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique treatment approach that combines multiple therapies to target specific characteristics of the disease. This study stands out because it focuses on a personalized treatment plan that adapts to the individual patient's needs, potentially improving outcomes. By utilizing a combination of therapies, the goal is to enhance the effectiveness of treatment and provide better management options for patients.
Third Opinion AI Generated Synopsis

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT05530421
Age 18 +
Sex Both
Phase Phase 2
This research aims to find out if treating patients with translocation 11;14-positive, relapsed/refractory myeloma using a combination of selinexor, venetoclax, and dexamethasone therapy can enhance the effectiveness of anti-cancer treatment.
Third Opinion AI Generated Synopsis

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this study, researchers are exploring a new treatment approach that combines different therapies to enhance effectiveness against the disease. What makes this trial unique is its focus on using a combination of existing treatments in a specific sequence, which may improve patient outcomes. This innovative strategy aims to better target the disease and potentially lead to more effective management of symptoms.
Third Opinion AI Generated Synopsis

CART-38 in Adult AML and MM Patients
NCT05442580
Age 18 +
Sex Both
Phase Phase 1
This study aims to assess the safety and feasibility of using CART-38 cells, a type of T cells modified with anti-CD38 receptors, in patients with Acute Myeloid Leukemia and Multiple Myeloma. The study will evaluate the potential benefits of this treatment for these types of cancer.
Third Opinion AI Generated Synopsis

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552
Age 18 +
Sex Both
Phase Phase 2
This study aims to determine whether talquetamab is effective in treating relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s). It will be evaluated in Part 3 of the study.
Third Opinion AI Generated Synopsis

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
NCT03309111
Age 18 +
Sex Both
Phase Phase 1
This study will investigate the safety, effectiveness, and immune response of ISB 1342 in patients with relapsed or refractory multiple myeloma. The researchers will also examine how the drug is processed and how it affects the body.
Third Opinion AI Generated Synopsis

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
NCT05391750
Age 18 +
Sex Both
Phase Phase 1
Researchers are conducting a phase I trial to determine the best dosage and side effects of venetoclax and tocilizumab in treating t(11;14) multiple myeloma that has relapsed or is refractory, wherein venetoclax blocks the protein Bcl-2 to stop cancer cell growth, and tocilizumab may interfere with tumor cell growth and spread while also treating immune therapy side effects. The study's goal is to increase cancer cell death with this combination.
Third Opinion AI Generated Synopsis

64Cu-LLP2A for Imaging Hematologic Malignancies
NCT06636175
Age 18 +
Sex Both
Phase Early Phase 1
This clinical study focuses on a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its emphasis on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to evaluate how well these combined treatments work in managing the condition and potentially offering better options for patients.
Third Opinion AI Generated Synopsis

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
NCT04398485
Age 18 +
Sex Both
Phase Phase 1
This study aims to find out the highest dose of ION251 that can be tolerated by patients who have relapsed or refractory multiple myeloma and to recommend a suitable dose for Phase 2 trials.
Third Opinion AI Generated Synopsis

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT02675452
Age 18 - 85
Sex Both
Phase Phase 1
AMG 176 has been found to be safe and tolerable for patients with relapsed or refractory multiple myeloma and acute myeloid leukemia.
Third Opinion AI Generated Synopsis

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03110822
Age 18 +
Sex Both
Phase Phase 1
Researchers are conducting a study to determine if combining ruxolitinib, steroids, and lenalidomide is safe and effective in treating multiple myeloma patients who are experiencing disease progression. The study is open-label and multicenter, and it is in phase 1.
Third Opinion AI Generated Synopsis

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
NCT04176380
Age 18 +
Sex Both
Phase Phase 2
The RAPA-201-RRMM study is a clinical trial that investigates the use of autologous T cells in adults with relapsed and refractory multiple myeloma who have undergone at least three prior treatments. It is an open-label, single-arm, non-randomised multicentre phase II study.
Third Opinion AI Generated Synopsis

A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
NCT03017820
Age 18 +
Sex Both
Phase Phase 1
This clinical trial aims to find the best dosage and potential side effects of VSV-hIFNbeta-NIS virus, which may be able to destroy cancer cells without harming healthy ones. Researchers will test the virus on patients with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma for whom other treatments have been ineffective, and will also measure the effectiveness of ruxolitinib phosphate in stopping tumor growth.
Third Opinion AI Generated Synopsis

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
NCT04557150
Age 18 +
Sex Both
Phase
This study aims to test the safety and effectiveness of RO7425781, a new treatment for people diagnosed with relapsed or refractory multiple myeloma. The study has two parts and it will include participants who have not responded to standard-of-care treatments or are unable to tolerate them.
Third Opinion AI Generated Synopsis

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Age 18 +
Sex Both
Phase Phase 3
The trial will study the effectiveness and safety of SPd versus EloPd in patients with multiple myeloma who have previously received 1 to 4 anti-MM treatments and an IMiD, PI, and anti-CD38 mAb, with a focus on their HR-QoL impact. It is a randomized, open-label multicenter phase 3 trial.
Third Opinion AI Generated Synopsis

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
NCT05093335
Age 18 +
Sex Both
Phase Early Phase 1
The study focuses on a unique approach to treating patients by combining different therapies that target the disease in various ways. It aims to improve treatment outcomes by using a specific regimen that includes both established and novel agents, potentially leading to better management of the condition. This innovative strategy may offer new hope for patients seeking effective treatment options.
Third Opinion AI Generated Synopsis

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
NCT05336383
Age 18 +
Sex Both
Phase Phase 2
This study will test the safety and effectiveness of salvage radiation treatment after BCMA CAR-T therapy in people with relapsed and refractory multiple myeloma who have active disease. The primary goals are to determine the objective response rate and duration of response among responders.
Third Opinion AI Generated Synopsis

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT05363111
Age 18 +
Sex Both
Phase Phase 1
This clinical trial is testing the safety and effectiveness of a combination of three treatments (daratumumab, 111In-DOTA-daratumumab, and 225Ac-DOTA-daratumumab) for multiple myeloma that does not respond to treatment or has come back. The treatments work by interfering with cancer cell growth and delivering targeted radiation to kill more cancer cells.
Third Opinion AI Generated Synopsis

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320
Age 18 +
Sex Both
Phase Phase 3
This study aims to compare the effectiveness of two combinations of talquetamab subcutaneously with daratumumab and pomalidomide, and with only daratumumab, respectively, with the combination of daratumumab, pomalidomide, and dexamethasone (DPd).
Third Opinion AI Generated Synopsis

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976
Age 18 +
Sex Both
Phase Phase 3
The study aims to compare the effectiveness of CC-92480 with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM. The purpose is to find out which treatment is more effective.
Third Opinion AI Generated Synopsis

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335
Age 18 +
Sex Both
Phase Phase 1
The study focuses on a unique approach to treating patients with a specific type of blood cancer by using a combination of therapies that target the disease in different ways. It aims to improve patient outcomes by enhancing the effectiveness of existing treatments while minimizing side effects. This innovative strategy may offer new hope for individuals seeking more effective management of their condition.
Third Opinion AI Generated Synopsis

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
NCT06105554
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to evaluate how well this combination works compared to standard treatments, potentially offering a more effective option for managing the disease.
Third Opinion AI Generated Synopsis

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
NCT06106945
Age 18 +
Sex Both
Phase Phase 1, Phase 2
This clinical study focuses on a unique combination of treatments for patients with Multiple Myeloma, utilizing a specific approach that includes both established therapies and innovative strategies. It aims to evaluate the effectiveness of this combination in improving patient outcomes and managing the disease more effectively. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Relapsed
NCT06152575
Age 18 +
Sex Both
Phase Phase 3
The study focuses on a unique approach to treating Multiple Myeloma by combining different therapies to enhance patient outcomes. It aims to evaluate the effectiveness of a specific treatment regimen that includes both established and novel agents, potentially leading to improved management of the condition. This trial is particularly notable for its emphasis on personalized treatment strategies tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
NCT06209606
Age 18 +
Sex Both
Phase Early Phase 1
In this clinical study, researchers are exploring a unique approach to treatment by using a combination of therapies that target specific characteristics of the disease. This study stands out because it focuses on personalized treatment plans based on individual patient profiles, which may lead to more effective outcomes. By integrating various treatment modalities, the study aims to improve the overall management of the condition and enhance patient quality of life.
Third Opinion AI Generated Synopsis

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique approach to treating patients by combining different therapies to enhance effectiveness. The study focuses on a specific treatment regimen that aims to improve patient outcomes by targeting the disease more effectively. This innovative strategy may offer new hope for individuals seeking better management options.
Third Opinion AI Generated Synopsis

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
NCT05153330
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to assess how well these combined treatments work compared to standard options, potentially offering a more effective solution for managing the condition.
Third Opinion AI Generated Synopsis

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
NCT04283097
Age 18 +
Sex Both
Phase Phase 1
The study will test a drug called KPG-818 in combination with dexamethasone in adult subjects with multiple myeloma, and as a monotherapy in subjects with other hematological malignancies. The goal is to determine safe and effective doses for further studies.
Third Opinion AI Generated Synopsis

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
NCT02512926
Age 6 - 29
Sex Both
Phase Phase 1
A study is being conducted to determine the safety and maximum tolerated dose of carfilzomib when used in combination with cyclophosphamide and etoposide for treating pediatric patients with relapsed/refractory solid tumors or leukemia, as carfilzomib is FDA approved for adults with multiple myeloma but not for children.
Third Opinion AI Generated Synopsis

Personalized NK Cell Therapy in CBT
NCT02727803
Age 15 - 80
Sex Both
Phase Phase 2
This clinical trial tests personalized natural killer (NK) cell therapy for patients with certain types of cancer after chemotherapy and umbilical cord blood transplant. The therapy uses NK cells to kill remaining tumor cells and potentially reduce the risk of complications after transplant.
Third Opinion AI Generated Synopsis

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03399799
Age 18 +
Sex Both
Phase Phase 1
This study aims to determine the safe dose and schedule for Talquetamab and further assess its safety in participants. The study is divided into two parts: dose escalation and dose expansion.
Third Opinion AI Generated Synopsis

Optimizing PTCy Dose and Timing
NCT03983850
Age 12 - 120
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to improve outcomes for patients. What makes this trial unique is its focus on using a combination of existing treatments in a novel way, which may enhance effectiveness and reduce side effects. This could potentially lead to better management of the condition and improved quality of life for patients.
Third Opinion AI Generated Synopsis

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572
Age 13 +
Sex Both
Phase Phase 1
This study focuses on a unique approach to treating patients with a specific type of therapy that combines multiple treatment strategies. It aims to evaluate the effectiveness of this combination in improving patient outcomes and quality of life. The study is notable for its emphasis on personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
NCT05327023
Age 12 - 120
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach that combines a specific type of therapy with a focus on high-risk patients. This study stands out because it aims to evaluate the effectiveness of this combination in improving patient outcomes, particularly for those who may not respond well to standard treatments. By targeting a specific patient population, the study hopes to provide new insights into more effective treatment options.
Third Opinion AI Generated Synopsis

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
NCT05461209
Age 18 +
Sex Both
Phase Phase 3
This study aims to determine whether talquetamab or belantamab mafodotin is more effective in terms of overall response rate or progression-free survival.
Third Opinion AI Generated Synopsis

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
NCT05645107
Age 18 +
Sex Both
Phase Phase 3
The study focuses on a unique approach to treatment by combining various therapies to enhance effectiveness against the disease. It aims to evaluate the impact of this combination on patient outcomes, potentially leading to improved management strategies. This innovative method may offer new hope for patients by targeting the disease more effectively than traditional treatments.
Third Opinion AI Generated Synopsis

Cevostamab Following CAR T Cell Therapy for RRMM
NCT05801939
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines different therapies to enhance effectiveness. What makes this trial unique is its focus on a specific combination of therapies that have not been widely tested together, potentially leading to improved outcomes. The study aims to assess how well this combination works in managing the disease and improving patients' quality of life.
Third Opinion AI Generated Synopsis

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
NCT05887167
Age 18 - 85
Sex Both
Phase Phase 1
The study focuses on a unique approach to treating patients by combining different therapies to enhance effectiveness. It aims to evaluate the safety and efficacy of this combination in managing the condition, potentially leading to improved outcomes for patients. By exploring various treatment strategies, the study seeks to provide new insights into more effective management options.
Third Opinion AI Generated Synopsis

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
NCT06066359
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining multiple therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to assess how well this combination works compared to standard treatments.
Third Opinion AI Generated Synopsis

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150
Age 18 +
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a unique combination of treatments for patients with Multiple Myeloma, focusing on the use of a specific drug alongside other therapies. This approach aims to enhance the effectiveness of treatment by targeting the disease from multiple angles, potentially leading to better outcomes. The study also emphasizes the importance of personalized treatment plans based on individual patient needs.
Third Opinion AI Generated Synopsis

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (LINKER-AL2)
NCT06292780
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach that combines a specific drug regimen with a focus on patient participation and monitoring. The study aims to assess the effectiveness of this treatment in managing symptoms and improving the quality of life for participants. By involving patients actively in their care, the study seeks to enhance treatment outcomes and provide valuable insights into personalized therapy options.
Third Opinion AI Generated Synopsis

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06356571
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique approach to treating patients by using a combination of therapies that target specific aspects of the disease. The study focuses on a new method that combines different treatment strategies to enhance effectiveness and improve patient outcomes. This innovative approach aims to provide a more personalized treatment plan for individuals, potentially leading to better management of their condition.
Third Opinion AI Generated Synopsis

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity (Talisman)(Replased)
NCT06500884
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to improve outcomes for patients. What makes this trial unique is its focus on personalized treatment plans based on individual responses, which could lead to more effective management of the condition. This innovative strategy aims to enhance the overall effectiveness of existing treatments and provide better options for patients.
Third Opinion AI Generated Synopsis